FY21 Guidance (see table at footer for comparisons)
Revenue: FY21 guidance, $118-$122m
Underlying EBITDA: $21-$22m
Underlying EPS: 10.0-11.0 cps
- We continue to see a strong level of inquiry from existing and new customers including to onshore manufacturing;
- Pharmaceutical product categories that have been affected by the health measures put in place to respond to Covid-19 are expected to improve progressively through the first half of FY22 and normalise through the second half.
- Demand has already started to return coupled with the clearing of stock on hand in the channel. The latest unfortunate lockdown in Victoria has had a minor negative impact on the Group’s FY21 earnings.
- The Multipack-LJM acquisition was successfully completed in January 2021 and has performed in line with expectations for the first 6 months with its earnings seasonally weighted to the July to December half.
- The Group is now focused on leveraging Multipack-LJM’s capabilities and high-quality customer base to drive the next phase of growth
- The NSW site consolidation strategy is being progressed and we expect this to be materially accretive for shareholders in the medium term
- We continue to assess a range of accretive M&A opportunities, with a focus on bolt-ons that bring new customers, synergy potential or strategic acquisitions that expand our capabilities.
About Probiotec
Probiotec Limited is a manufacturer, packer and distributor of a range of prescription and over-the-counter (OTC) pharmaceuticals, complementary medicines, FMCG and consumer health products. The company owns five manufacturing facilities in Australia and distributes its products both domestically and internationally. Products are manufactured by Probiotec on behalf of a range of clients, including major international companies.
ASX Announcement